...
首页> 外文期刊>Journal of Pharmacological and Toxicological Methods >Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.
【24h】

Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.

机译:使用IonWorks HT优化和验证基于中通量电生理的hERG测定。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: Regulatory and competitive pressure to reduce the QT interval prolongation risk of potential new drugs has led to focus on methods to test for inhibition of the human ether-a-go-go-related gene (hERG)-encoded K+ channel, the primary molecular target underlying this safety issue. Here we describe the validation of a method that combines medium-throughput with direct assessment of channel function. METHODS: The electrophysiological and pharmacological properties of hERG were compared using two methods: conventional, low-throughput electrophysiology and planar-array-based, medium-throughput electrophysiology (IonWorks HT). A pharmacological comparison was also made between IonWorks HT and an indirect assay (Rb+ efflux). RESULTS: Basic electrophysiological properties of hERG were similar whether recorded conventionally (HEK cells) or using IonWorks HT (CHO cells): for example, tail current V1/2 -12.1+/-5.0 mV (32) for conventional and -9.5+/-6.0 mV (46) for IonWorks HT (mean+/-S.D. (n)). A key finding was that as the number of cells per well was increased in IonWorks HT, the potency reported for a given compound decreased. Using the lowest possible cell concentration (250,000 cells/ml) and 89 compounds spanning a broad potency range, the pIC50 values from IonWorks HT (CHO-hERG) were found to correlate well with those obtained using conventional methodology (HEK-hERG)(r=0.90; p<0.001). Further validation using CHO-hERG cells with both methods confirmed the correlation (r=0.94; p<0.001). In contrast, a comparison of IonWorks HT and Rb+ efflux data with 649 compounds using CHO-hERG cells showed that the indirect assay consistently reported compounds as being, on average, 6-fold less potent, though the differences varied depending on chemical series. DISCUSSION: The main finding of this work is that providing a relatively low cell concentration is used in IonWorks HT, the potency information generated correlates well with that determined using conventional electrophysiology. The effect on potency of increasing cell concentration may relate to a reduced free concentration of test compound owing to partitioning into cell membranes. In summary, the IonWorks HT hERG assay can generate pIC50 values based on a direct assessment of channel function in a timeframe short enough to influence chemical design.
机译:简介:为降低潜在新药的QT间隔延长风险而采取的监管和竞争压力已导致人们侧重于测试抑制人类以太相关基因(hERG)编码的K +通道(主要途径)的方法这个安全问题的分子靶标。在这里,我们描述了将中吞吐量与通道功能的直接评估相结合的方法的验证。方法:使用两种方法比较了hERG的电生理学和药理学特性:传统的低通量电生理学和基于平面阵列的中通量电生理学(IonWorks HT)。在IonWorks HT和间接测定(Rb +外排)之间也进行了药理比较。结果:无论是常规记录(HEK细胞)还是使用IonWorks HT(CHO细胞)记录,hERG的基本电生理特性均相似:例如,常规电流为-1/2的尾电流V1 / 2 -12.1 +/- 5.0 mV(-9.5 + / -IonWorks HT为-6.0 mV(46)(平均值+/- SD(n))。一个关键发现是,随着IonWorks HT中每孔细胞数量的增加,报告给定化合物的效价降低。使用最低的可能的细胞浓度(250,000个细胞/ ml)和89个化合物,它们的效价范围很广,发现IonWorks HT(CHO-hERG)的pIC50值与使用常规方法(HEK-hERG)获得的pIC50很好相关(r = 0.90; p <0.001)。两种方法均使用CHO-hERG细胞进行进一步验证,证实了相关性(r = 0.94; p <0.001)。相比之下,使用CHO-hERG细胞对649种化合物的IonWorks HT和Rb +外排数据进行的比较显示,间接测定法一致地报告化合物的效力平均降低了6倍,尽管差异取决于化学系列。讨论:这项工作的主要发现是,如果在IonWorks HT中使用相对较低的细胞浓度,则产生的效价信息与使用常规电生理学测定的信息高度相关。对增加细胞浓度的效力的影响可能与由于分配到细胞膜中而导致测试化合物的自由浓度降低有关。总而言之,IonWorks HT hERG分析可以在足够短的时间内影响通道设计的基础上直接评估通道功能,从而产生pIC50值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号